Traditional Medicine Frameworks: TCM, Ayurveda AYUSH, Kampo, Western Herbal and Cross-Market Positioning

TCM is regulated by China National Medical Products Administration (NMPA) as Chinese Medicine under the Drug Administration Law with classification into Chinese Crude Drugs (Chinese herbal medicinals), Decoction Pieces (processed Chinese herbal medicinals), Chinese Medicine Preparations (traditional patent medicines) and Innovative Chinese Medicines (modern formulations of traditional active principles). NMPA Chinese Medicine registration follows the Drug Registration Regulation with specific Chinese Medicine pathways including classical formulae (经典名方) — a fast-track for traditional formulations from authoritative classical texts (Han, Tang, Song, Jin, Yuan, Ming, Qing dynasty medical canon) that may be approved on traditional-use evidence with reduced clinical-trial requirements. Manufacturing requires Chinese Medicine GMP per the Drug Production Quality Management Practice with traditional processing standards (paozhi 炮制) for botanical decoction pieces. The Chinese Pharmacopoeia maintains official monographs for over 600 Chinese herbal medicinals with identification, purity, content and quality specifications. Cross-border TCM supplement positioning — export of TCM-positioned products to non-China markets requires national framework alignment (US DSHEA structure/function, EU food supplement or THMPD herbal medicine, Japan FFC functional food) and cannot rely on China NMPA Chinese Medicine status as evidence elsewhere.

India Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha, Sowa Rigpa and Homoeopathy) regulates traditional medicine systems under the Drugs and Cosmetics Act with AYUSH-specific schedules and the Ayurvedic, Siddha and Unani Drugs Consultative Committee. AYUSH manufacturing requires GMP per Schedule T of the Drugs and Cosmetics Rules, ingredient sourcing per the Ayurvedic Pharmacopoeia of India / Unani Pharmacopoeia of India / Siddha Pharmacopoeia of India, and product registration per the AYUSH framework. The Ayurvedic Pharmacopoeia maintains monographs for over 600 single drugs and compound formulations with botanical identification (Sanskrit/Hindi/English nomenclature with Latin binomial), Ayurvedic pharmacological properties (rasa, virya, vipaka, prabhava), processing methods (samskara) and analytical specifications. Cross-border Ayurvedic supplement positioning — export of Ayurvedic products to US relies on dietary supplement framework with DSHEA structure/function claims and NDI notification for ingredients not marketed pre-1994; EU export operates under food supplement or Traditional Herbal Medicinal Products Directive 2004/24/EC; UK MHRA THR scheme has registered specific Ayurvedic products. Heavy-metal content in Ayurvedic preparations is a recurrent regulatory issue across export markets — California Prop 65 lead enforcement, FDA Import Alerts and EU heavy-metal limits drive testing and reformulation pressure.

Kampo (漢方) is regulated by Japan Pharmaceuticals and Medical Devices Agency (PMDA) as Kampo medicine under the Pharmaceutical Affairs Act with two distinct categories — Kampo Crude Drugs (single botanical materials, regulated per Japanese Pharmacopoeia monographs) and Kampo Formulations (traditional Japanese adaptations of Chinese classical formulae, regulated as prescription pharmaceuticals or as OTC depending on formulation and indication). The Ministry of Health, Labour and Welfare (MHLW) maintains a fixed list of 148 standard Kampo formulations covered under Japan's national health insurance, each with defined composition, dose and approved indication. Kampo manufacturing requires Japan PMDA GMP with Japanese Pharmacopoeia Kampo Crude Drug monograph compliance and Kampo-specific decoction and extract standardisation. The Kampo framework is distinct from the Foods with Function Claims (FFC) and Foods for Specified Health Uses (FOSHU) supplement frameworks — Kampo formulations cannot be marketed as supplements and vice versa. Cross-border Kampo positioning — export of Kampo-positioned products requires destination-market framework alignment; the Japanese Pharmaceutical Affairs Act Kampo authorisation is not portable to non-Japan markets.

EU Traditional Herbal Medicinal Products Directive 2004/24/EC amending Directive 2001/83/EC established a simplified registration pathway for traditional herbal medicinal products with documented 30+ years of traditional use including at least 15 years in the EU. Registration requires reduced quality and safety dossier compared to full marketing authorisation, traditional-use evidence (literature, bibliographic, market history), Member State competent authority registration (national-level rather than EMA centralised) and labelling as 'traditional herbal medicinal product used for [indication] exclusively based on long-standing use'. The Herbal Medicinal Products Committee (HMPC) at EMA publishes Community Herbal Monographs (List of Herbal Substances, Preparations and Combinations Thereof) as references for registration. UK MHRA Traditional Herbal Registration (THR) scheme operates the equivalent UK-post-Brexit framework. US framework for traditional herbal positioning operates under DSHEA dietary supplement with structure/function claims, with FDA-acceptable traditional-use evidence supporting NDI notifications. Cross-market positioning discipline — traditional-medicine positioning in one market does not transfer to another; a US DSHEA dietary supplement is not an EU THMPD traditional herbal medicinal product and vice versa; products marketed cross-region typically operate multiple parallel regulatory positionings with market-specific claim copy.